Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 2
---
 an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to Completion
Supplement Dated November 5, 2025 to
Proxy Statement/Prospectus Dated September 9, 2025

| SUPPLEMENT TO              |
| PROXY STATEMENT/PROSPECTUS |

NEWCELX LTD. NewcelX Ltd., or NewcelX, as successor to NLS Pharmaceutics Ltd., or NLS, previously registered with the U.S. Securities and Exchange Commission, or the SEC, 70,000,000 common shares, 0.03 Swiss Franc (CHF) par value per share, or the NLS Common Shares, and up to 70,000,000 pre-funded warrants to purchase 70,000,000 NLS Common Shares. NLS previously filed with the U.S. Securities and Exchange Commission, or the SEC, a Proxy Statement/Prospectus dated as of September 9, 2025, or the Prospectus, relating to the NLS Common Shares and pre-funded warrants to purchase NLS Common Shares. This prospectus supplement, or the Supplement, includes (i) NLS’s Unaudited Interim Condensed Financial Statements as of June 30, 2025 and December 31, 2024 and for the six months ended June 30, 2025 and 2024; (ii) NLS’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2025; (iii) Kadimastem Ltd.’s, an Israeli publicly traded company limited by shares (TASE: KDST), or Kadimastem, Interim Condensed Financial Statements as of and for the six months ended June 30, 2025; (iv) Kadimastem’s Audited Financial Statements as of and for the years ended December 31, 2024 and 2023; and (v) NLS’s Unaudited Pro Forma Condensed Combined Financial Statements as of and for the six months ended June 30, 2025. Updates the information contained in the Prospectus and should be read together with the information in the Prospectus. The updates contained in this Supplement supersede any conflicting information contained in the Prospectus. NewcelX’s common shares, 0.05 Swiss Franc (CHF) par value per share, or New